Inactive Instrument

Metacrine, Inc.

Equities

MTCR

US59101E1038

Biotechnology & Medical Research

Metacrine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

March 30, 2022 at 04:16 pm EDT

Metacrine, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 62.21 million compared to USD 37.3 million a year ago. Basic loss per share from continuing operations was USD 2.29 compared to USD 3.97 a year ago.

Latest news about Metacrine, Inc.

Metacrine, Inc. Announces Board Changes	23-03-23	CI
Metacrine, Inc. Announces CEO Changes	23-03-23	CI
Metacrine, Inc.(OTCPK:MTCR) dropped from S&P TMI Index	23-02-13	CI
Metacrine, Inc.(OTCPK:MTCR) dropped from NASDAQ Composite Index	23-02-08	CI
Metacrine, Inc. Appoints Michael York as President	23-02-03	CI
Metacrine, Inc. Appoints Michael York as Chief Executive Officer	23-02-03	CI
Insider Sell: Metacrine	23-01-27	MT
North American Morning Briefing : China Optimism Gives Boost to Futures	22-12-27	DJ
Equillium, Metacrine Agree to Terminate Proposed Merger	22-12-27	MT
Metacrine, Equillium Mutually Agree to Terminate Merger Accord	22-12-23	MT
Equillium, Inc. (NasdaqGM:EQ) cancelled the acquisition of Metacrine, Inc. from a group of shareholders.	22-12-22	CI
Insider Buy: Metacrine	22-12-21	MT
Metacrine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Insider Buy: Metacrine	22-10-31	MT
Metacrine, Inc. Enters into A License Agreement with FL2022-001, Inc	22-10-11	CI
Health Care Up as Investors Rotate Back into Bull-Market Leaders -- Health Care Roundup	22-09-07	DJ
Transcript : Equillium, Inc., Metacrine, Inc. - M&A Call	22-09-07
Equillium to Acquire Biopharmaceutical Company Metacrine in All-Stock Deal	22-09-06	MT
Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. from a group of shareholders.	22-09-05	CI
Metacrine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Metacrine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Metacrine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Metacrine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-03-30	CI
Metacrine, Inc. Enters into an Agreement for Termination of Lease	22-03-15	CI
Metacrine, Inc. Announces Patricia Millican to Retire as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Effective as of March 31, 2022	22-03-03	CI

Chart Metacrine, Inc.

Duration

Period

More charts

Company Profile

Metacrine, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases. The Companyâs advanced program targets the farnesoid X receptor (FXR), which is central to modulating GI and liver diseases. The Companyâs pipeline includes MET642 and hydroxysteroid dehydrogenase 17B13 (HSD17B13 or HSD). MET642 is used for the treatment of inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohnâs disease. HSD17B13 is used for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company is pursuing the development of MET642 for the treatment of Ulcerative Colitis (UC). The Company has built a proprietary library of approximately 2,500 FXR compounds.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+48.77%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research